AlphaMark Advisors LLC cut its position in shares of Amgen (NASDAQ:AMGN) by 5.5% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,973 shares of the medical research company’s stock after selling 1,638 shares during the period. Amgen comprises about 2.0% of AlphaMark Advisors LLC’s investment portfolio, making the stock its 7th largest position. AlphaMark Advisors LLC’s holdings in Amgen were worth $4,769,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMGN. Geode Capital Management LLC grew its position in Amgen by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 8,110,133 shares of the medical research company’s stock valued at $1,407,552,000 after acquiring an additional 199,838 shares during the period. Renaissance Technologies LLC grew its position in Amgen by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 4,579,445 shares of the medical research company’s stock valued at $796,365,000 after acquiring an additional 661,745 shares during the period. LSV Asset Management grew its position in Amgen by 5.6% in the first quarter. LSV Asset Management now owns 4,028,784 shares of the medical research company’s stock valued at $686,827,000 after acquiring an additional 214,013 shares during the period. Legal & General Group Plc grew its position in Amgen by 1.6% in the third quarter. Legal & General Group Plc now owns 3,781,891 shares of the medical research company’s stock valued at $705,099,000 after acquiring an additional 60,532 shares during the period. Finally, Schwab Charles Investment Management Inc. grew its position in Amgen by 3.9% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 3,304,340 shares of the medical research company’s stock valued at $574,680,000 after acquiring an additional 123,250 shares during the period. Institutional investors and hedge funds own 78.43% of the company’s stock.
Get Amgen alerts:
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $189.75, for a total value of $289,368.75. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 4,575 shares of company stock worth $818,208 in the last ninety days. 0.19% of the stock is currently owned by insiders.
Shares of Amgen opened at $178.24 on Monday, according to MarketBeat Ratings. The company has a current ratio of 3.88, a quick ratio of 3.60 and a debt-to-equity ratio of 2.14. Amgen has a 12-month low of $153.56 and a 12-month high of $201.23. The firm has a market cap of $117.94 billion, a PE ratio of 14.17, a PEG ratio of 2.22 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, April 24th. The medical research company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.24 by $0.23. Amgen had a return on equity of 35.80% and a net margin of 9.67%. The business had revenue of $5.55 billion for the quarter, compared to analyst estimates of $5.44 billion. During the same quarter in the prior year, the firm posted $3.15 earnings per share. The firm’s revenue for the quarter was up 1.6% compared to the same quarter last year. research analysts anticipate that Amgen will post 13.63 EPS for the current fiscal year.
Amgen declared that its board has authorized a stock repurchase plan on Thursday, February 1st that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy shares of its stock through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its stock is undervalued.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be paid a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a dividend yield of 2.96%. The ex-dividend date is Wednesday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 41.97%.
Several brokerages have recently commented on AMGN. Cowen restated a “buy” rating and set a $204.00 target price on shares of Amgen in a report on Friday, February 2nd. Mizuho restated a “buy” rating and set a $192.00 target price on shares of Amgen in a report on Thursday, February 1st. Oppenheimer restated a “buy” rating and set a $205.00 target price on shares of Amgen in a report on Tuesday, January 30th. Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $194.00 target price on the stock in a report on Thursday, April 5th. Finally, TheStreet cut Amgen from a “b-” rating to a “c+” rating in a report on Wednesday, April 11th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $191.70.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen (NASDAQ:AMGN).